Incidence of Hospitalized Infection in Elderly Patients with Rheumatoid Arthritis on bDMARDs and tsDMARDs: A Healthcare Data-Based Cohort Study
- Conditions
- Rheumatoid Arthritis
- Registration Number
- JPRN-UMIN000037851
- Lead Sponsor
- CHUGAI PHARMACEUTICAL CO.,LTD. MEDICAL SCIENCE DEPT
- Brief Summary
Crude incidence rates (/100 person-years) of HIs were 3.99, 7.27, and 10.77, respectively. In the oldest group, aRRs (95% confidence interval) for HIs (b/tsDMARDs versus TCZ) were as follows: etanercept, 2.40 (1.24-4.61), adalimumab, 1.90 (0.75-4.83), golimumab, 1.21 (0.66-2.23), and abatacept, 0.89 (0.49-1.62). In the other age groups, the noticeable difference was a lower aRR of etanercept versus TCZ in the youngest group (0.30, 0.11-0.85).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 5506
Not provided
1. Patients in hospital at baseline 2. Patients with other diseases indicated for the study therapy (behcet's disease, psoriasis, ankylosing spondylitis, kawasaki disease, crohn's disease, ulcerative colitis, juvenile idiopathic arthritis/adult still's disease, suppurative hidradenitis, castleman's disease, giant cell arteritis, takayasu's arteritis) at least once in the previous year
Study & Design
- Study Type
- Others,meta-analysis etc
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method umber of infections requiring first hospitalized infection, morbidity (person-years), crude morbidity, crude hazard ratio of each bDMARDs and tsDMARDs to tocilizumab, adjusted hazard ratio, in elderly RA patients aged 75 years and older
- Secondary Outcome Measures
Name Time Method